Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study

  • Authors:
    • Miwako Omori
    • Yusuke Okuma
    • Taiki Hakozaki
    • Yukio Hosomi
  • View Affiliations

  • Published online on: November 13, 2018     https://doi.org/10.3892/mco.2018.1765
  • Pages: 137-143
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There are a number of suggested predictive factors of nivolumab for non‑small cell lung cancer (NSCLC), however, there is not enough evidence to determine a single factor that can predict the efficacy of nivolumab. As the progress of biomarkers for cancer treatment is improving, it has been speculated that certain clinical factors serve an important role when predicting the outcome of chemotherapy. A total of 67 patients treated with nivolumab for NSCLC from 2016‑2017 were prospectively investigated. Age, sex, the Eastern Cooperative Oncology Group Performance Status, histology, epidermal growth factor receptor (EGFR) mutation, history of chemotherapy, smoking status, use of statins, use of fibrates, use of dipeptidyl peptidase‑4 (DPP‑4) inhibitors, and use of metformin were examined as clinical factors. Statistical analyses were performed using the Kaplan‑Meier method and Cox regression adjusted for risk factors and the tumor response of 67 patients was assessed. The patients had a median age of 67 years (range, 36‑87 years), and 46 males and 21 females were enrolled; performance status 0/1 was 59. Cases were categorized as adenocarcinoma (n=41), squamous cell carcinoma (n=17) and other (n=9). A total of 13 patients (19.4%) had EGFR mutations. These clinical factors were not statistically significant in overall survival (OS). Clinical laboratory findings, complications and use of medical agents including antidiabetes mellitus or lipidemia were also analyzed. Statins exhibited statistical significance for response (P=0.02). Time‑to‑treatment failure (TTF) in statin‑use group was not reached [95% confidence interval (CI): 1.9‑not reached] and was 4.0 months (95% CI: 2.0‑5.4) in the non‑statin group (P=0.039). The median OS in statin‑use group was not reached (95% CI: 8.7‑not reached) and was 16.5 months (95% CI: 7.5‑not reached) in the non‑statin group (P=0.058). NSCLC patients previously treated with nivolumab who were administered statins exhibited an increased response rate and longer TTF. This response was not statistically significant in OS.
View Figures
View References

Related Articles

Journal Cover

January 2019
Volume 10 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Omori, M., Okuma, Y., Hakozaki, T., & Hosomi, Y. (2019). Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study. Molecular and Clinical Oncology, 10, 137-143. https://doi.org/10.3892/mco.2018.1765
MLA
Omori, M., Okuma, Y., Hakozaki, T., Hosomi, Y."Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study". Molecular and Clinical Oncology 10.1 (2019): 137-143.
Chicago
Omori, M., Okuma, Y., Hakozaki, T., Hosomi, Y."Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study". Molecular and Clinical Oncology 10, no. 1 (2019): 137-143. https://doi.org/10.3892/mco.2018.1765